Read by QxMD icon Read

HPV vaccines safety

Jing Huang, Jingcheng Du, Rui Duan, Xinyuan Zhang, Cui Tao, Yong Chen
Data from the Vaccine Adverse Event Reporting System (VAERS) contain spontaneously reported adverse events (AEs) from the public. It has been a major data source for detecting AEs and monitoring vaccine safety. As one major limitation of spontaneous surveillance systems, the VAERS reports by themselves sometimes do not provide enough information to answer certain research questions. For example, patient level demographics are very limited in VAERS due to the protection of patient privacy, such that investigation of differential AE rates across race/ethnicity groups cannot be conducted using VAERS data only...
2018: Frontiers in Pharmacology
Jie Wu, Gang Chen, Fang-Cheng Zhuang, Meng Gao, Chuan-Dong Wu, Zhan-Long He, Yun-Shui Jiang, Jian-Bo Li, Jia-Yuan Bao, Zi-An Mao
OBJECTIVE: This study aimed to: evaluate long-term toxicity and pharmacokinetic parameters; to identify the target organ of toxicity of a recombinant adenovirus vaccine expressing human papillomavirus 16 E6 and E7 proteins (HPV16 E6E7-Ad5 Vac) in primates; and to determine the specific immune response of this recombinant adenovirus vaccine. METHOD: HPV16 E6E7-Ad5 Vac (dose 4.68 × 109 IU/bottle) was administered to Macaca fascicularis ( M. fascicularis ) to evaluate its long-term toxicity...
2018: American Journal of Translational Research
Anne F Rositch, Melinda Krakow
In response to the accompanying article by Yih et al. (Am J Epidemiol. 2018;187(6):1269-1276), we highlight the importance of moving beyond epidemiologic research on human papillomavirus (HPV) vaccine safety to focus on translation of this strong evidence base into successful vaccine safety communication strategies to bolster vaccine uptake. The potential of the HPV vaccine to reduce cancer incidence is substantial, yet actual HPV vaccination rates in the United States are disappointingly low in comparison with other routine childhood vaccines with similar safety profiles...
June 1, 2018: American Journal of Epidemiology
Jorge L Cervantes, Amy Hoanganh Doan
Despite being more than ten years since its introduction, global acceptance to the human papillomavirus (HPV) vaccine is still low. The immunogenetic background of the host, and HPV antigen recognition, are important in natural HPV infection, and should be taken into account in the understanding of adverse autoimmune reactions by the HPV vaccine in certain groups. There is no doubt of the benefit of vaccines in the reduction of the incidence of infectious diseases, and in the case of HPV, the prevention of persistent infection that would lead to cervical cancer...
2018: Memórias do Instituto Oswaldo Cruz
Erin Y Liu, Leah M Smith, Anne K Ellis, Heather Whitaker, Barbara Law, Jeffrey C Kwong, Paddy Farrington, Linda E Lévesque
BACKGROUND: Despite demonstrated effectiveness in real-world settings, concerns persist regarding the safety of the quadrivalent human papillomavirus (HPV4) vaccine. We sought to assess the risk of autoimmune disorders following HPV4 vaccination among grade 8 girls eligible for Ontario's school-based HPV vaccination program. METHODS: We undertook a population-based retrospective cohort study using Ontario's administrative health and vaccination databases from 2007 to 2013...
May 28, 2018: CMAJ: Canadian Medical Association Journal, Journal de L'Association Medicale Canadienne
Manako Yamaguchi, Masayuki Sekine, Risa Kudo, Sosuke Adachi, Yutaka Ueda, Etsuko Miyagi, Megumi Hara, Sharon J B Hanley, Takayuki Enomoto
Japan has no national vaccine registry and approximately 1700 municipalities manage the immunization records independently. In June 2013, proactive recommendations for the human papillomavirus (HPV) vaccine were suspended after unconfirmed reports of adverse events following immunization in the media, despite no vaccine safety signal having been raised. Furthermore, studies assessing HPV vaccine safety and effectiveness published post suspension are predominantly based on self-reported information. Our aim was to examine the accuracy of self-reported vaccination status compared with official municipal records...
May 25, 2018: Papillomavirus Research
S Marshall, A Fleming, A C Moore, L J Sahm
INTRODUCTION: Human papillomavirus (HPV) is the most common viral infection of the reproductive tract. Three prophylactic HPV vaccines are available for the prevention of HPV-related disease. Despite clinical success, immunisation rates remain sub-optimal. The purpose of this systematic review is to synthesise qualitative literature to achieve an understanding of the drivers and barriers to HPV vaccine acceptability and to determine targets for an intervention to improve vaccine uptake...
May 22, 2018: Research in Social & Administrative Pharmacy: RSAP
Sarah E Dilley, Sylvia Peral, J Michael Straughn, Isabel C Scarinci
The human papillomavirus (HPV) vaccine is an important tool for cancer prevention. However, vaccination rates in Alabama, a state with high rates of HPV-related cancers, remain below the national average. Our objective was to develop a comprehensive assessment of HPV vaccination in our state, with the goal to make recommendations for tailored multilevel interventions. A multimodal approach with quantitative and qualitative data was used to determine barriers and facilitators to HPV vaccination in Alabama. This included a survey of pediatric care providers and structured interviews with pediatricians, parents, nurses and community stakeholders...
May 22, 2018: Preventive Medicine
S L Deeks, M C Tunis, S Ismail
Background: Human papillomavirus (HPV) infections are the most common sexually transmitted infections. In the absence of vaccination, it is estimated that 75% of sexually active Canadians will have an HPV infection at some point in their lives. HPV vaccine programs were first recommended by Canada's National Advisory Committee on Immunization (NACI) in 2007. In addition to the existing HPV vaccine options in Canada, NACI recently recommended the use of a newly authorized nine-valent HPV (HPV9) vaccine according to a 3-dose immunization schedule for the prevention of HPV types 6-, 11-, 16-, 18-, 31-, 33-, 45-, 52- and 58-related cancers and anogenital warts in females aged 9 to 45 years and males aged 9 to 26 years...
June 1, 2017: Canada Communicable Disease Report, Relevé des Maladies Transmissibles Au Canada
S M Garland, P Pitisuttithum, H Y S Ngan, C-H Cho, C-Y Lee, C-A Chen, Y C Yang, T-Y Chu, N-F Twu, R Samakoses, Y Takeuchi, T H Cheung, S C Kim, L-M Huang, B-G Kim, Y-T Kim, K-H Kim, Y-S Song, S Lalwani, J-H Kang, M Sakamoto, H-S Ryu, N Bhatla, H Yoshikawa, M C Ellison, S R Han, E Moeller, S Murata, M Ritter, M Sawata, C Shields, A Walia, G Perez, A Luxembourg
Background: A 9-valent human papillomavirus-6/11/16/18/31/33/45/52/58 (9vHPV) vaccine extends coverage to 5 next most common oncogenic types (31/33/45/52/58) in cervical cancer versus quadrivalent HPV (qHPV) vaccine. We describe efficacy, immunogenicity, and safety in Asian participants (India, Hong Kong, South Korea, Japan, Taiwan, and Thailand) from 2 international studies: a randomized, double-blinded, qHPV vaccine-controlled efficacy study (young women aged 16-26 years; NCT00543543; Study 001); and an immunogenicity study (girls and boys aged 9-15 years; NCT00943722; Study 002)...
May 15, 2018: Journal of Infectious Diseases
Marc Arbyn, Lan Xu, Cindy Simoens, Pierre Pl Martin-Hirsch
BACKGROUND: Persistent infection with high-risk human papillomaviruses (hrHPV) types is causally linked with the development of cervical precancer and cancer. HPV types 16 and 18 cause approximately 70% of cervical cancers worldwide. OBJECTIVES: To evaluate the harms and protection of prophylactic human papillomaviruses (HPV) vaccines against cervical precancer and HPV16/18 infection in adolescent girls and women. SEARCH METHODS: We searched MEDLINE, Cochrane Central Register of Controlled Trials (CENTRAL) and Embase (June 2017) for reports on effects from trials...
May 9, 2018: Cochrane Database of Systematic Reviews
Jessica Kaufman, Rebecca Ryan, Louisa Walsh, Dell Horey, Julie Leask, Priscilla Robinson, Sophie Hill
BACKGROUND: Early childhood vaccination is an essential global public health practice that saves two to three million lives each year, but many children do not receive all the recommended vaccines. To achieve and maintain appropriate coverage rates, vaccination programmes rely on people having sufficient awareness and acceptance of vaccines.Face-to-face information or educational interventions are widely used to help parents understand why vaccines are important; explain where, how and when to access services; and address hesitancy and concerns about vaccine safety or efficacy...
May 8, 2018: Cochrane Database of Systematic Reviews
Peter A Newman, Carmen H Logie, Ashley Lacombe-Duncan, Philip Baiden, Suchon Tepjan, Clara Rubincam, Nick Doukas, Farid Asey
OBJECTIVE: To examine factors associated with parents' uptake of human papillomavirus (HPV) vaccines for their children. DESIGN: Systematic review and meta-analysis. DATA SOURCES: Cochrane Library, AIDSLINE, CINAHL, EMBASE, PsycINFO, Social Sciences Abstracts, Ovid MEDLINE, Scholars Portal, Social Sciences Citation Index and Dissertation Abstracts International from inception through November 2017. METHODS: We included studies that sampled parents and assessed uptake of HPV vaccines for their children (≤18 years) and/or sociodemographics, knowledge, attitudes or other factors associated with uptake...
April 20, 2018: BMJ Open
Julie Mouchet, Francesco Salvo, Emanuel Raschi, Elisabetta Poluzzi, Ippazio Cosimo Antonazzo, Fabrizio De Ponti, Bernard Bégaud
Approved in 2006, human papillomavirus (HPV) vaccines were initially targeted for girls aged 9-14 years. Although the safety of these vaccines has been monitored through post-licensure surveillance programmes, cases of neurological events have been reported worldwide. The present study aimed to assess the risk of developing demyelination after HPV immunization by meta-analysing risk estimates from pharmacoepidemiologic studies. A systematic review was conducted in Medline, Embase, ISI Web of Science and the Cochrane Library from inception to 10 May 2017, without language restriction...
April 14, 2018: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
Timothy J Wilkin, Huichao Chen, Michelle S Cespedes, Jorge T Leon-Cruz, Catherine Godfrey, Elizabeth Y Chiao, Barbara Bastow, Jennifer Webster-Cyriaque, Qinghua Feng, Joan Dragavon, Robert W Coombs, Rachel M Presti, Alfred Saah, Ross D Cranston
Background: Adults living with HIV are at increased risk for anal and oropharyngeal cancer caused by human papillomavirus (HPV). The efficacy of HPV vaccines in this population is unknown. Methods: Phase 3, double-blind, randomized controlled trial. We assigned HIV-infected adults age 27 or older to the quadrivalent HPV (Types 6, 11, 16, 18) vaccine or placebo (1:1) stratified by sex and presence of anal high-grade squamous intraepithelial lesions on biopsy (bHSIL)...
April 5, 2018: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
Maria J Abou El-Ola, Mariam A Rajab, Dania I Abdallah, Ismail A Fawaz, Lyn S Awad, Hani M Tamim, Ahmad O Ibrahim, Anas M Mugharbil, Rima A Moghnieh
Background: Human papillomavirus (HPV) infection is an established predisposing factor of cervical cancer. In this study, we assessed the awareness about genital warts, cervical cancer, and HPV vaccine among mothers having girls who are at the age of primary HPV vaccination attending a group of schools in Lebanon. We also assessed the rate of HPV vaccination among these girls and the barriers to vaccination in this community. Subjects and methods: This is a cross-sectional, school-based survey...
2018: Therapeutics and Clinical Risk Management
Jarim Kim
Despite the HPV vaccine’s efficacy in preventing cervical cancer, its coverage rates among Asians are very low. To increase immunization coverage among these populations, understanding the psychological factors that affect HPV acceptability is critical. To this end, this study examined the relationships between multidimensional health beliefs and HPV vaccine acceptance, and what information sources effectively foster HPV vaccination-related health beliefs. Data were collected using a survey of 323 undergraduate students in Korea...
April 4, 2018: International Journal of Environmental Research and Public Health
Abraham Degarege, Karl Krupp, Kristopher Fennie, Tan Li, Dionne P Stephens, Laura A V Marlow, Vijaya Srinivas, Anjali Arun, Purnima Madhivanan
STUDY OBJECTIVE: The aim of this study was to compare the parental attitudes and beliefs about human papillomavirus (HPV), cervical cancer, and HPV vaccine between urban and rural areas, India. DESIGN: Cross-sectional. SETTING: Mysore, India. PARTICIPANTS: Parents of school-going adolescent girls. INTERVENTIONS: Parents completed a self-administered questionnaire. MAIN OUTCOME MEASURES: Attitudes and beliefs about HPV, cervical cancer, and HPV vaccine...
March 26, 2018: Journal of Pediatric and Adolescent Gynecology
Kayla E Hanson, Brandon Koch, Kimberly Bonner, Annie-Laurie McRee, Nicole E Basta
Background: HPV vaccination uptake remains lower than other recommended adolescent vaccines in the United States. Parental attitudes are important predictors of vaccine uptake, yet little is known about how they have changed over time. Methods: Participants included U.S. residents aged 13-17 years with documented vaccination status who were unvaccinated (had not initiated) or undervaccinated (initiated, but had not completed) with the HPV vaccination series whose parents responded to the National Immunization Surveys-Teen, 2010-2015...
March 27, 2018: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
A Scott LaJoie, Jelani C Kerr, Richard D Clover, Diane M Harper
OBJECTIVE: The purpose of the study was to assess the knowledge, attitudes and beliefs of male and female college students in Kentucky about HPV associated diseases and vaccines, and to determine which parameters predicted self-reported uptake of HPV vaccination. MATERIALS AND METHODS: A self-selected cross-sectional sample of college students completed an evidence-based online survey. RESULTS: Of approximately 1200 potential respondents, 585 completed the survey...
June 2018: Papillomavirus Research
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"